RecruitingPhase 2NCT07659782

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients With Previously Treated, Advanced KRAS G12D-Mutated Non-Small Cell Lung Cancer (TARGET-D 202)

Sponsor

Verastem, Inc.

Enrollment

105 participants

Start Date

Jul 22, 2026

Study Type

INTERVENTIONAL

Conditions

Non-small Cell Lung Cancer

Summary

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cell Lung Cancer

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called VS-7375 for people with non-small cell lung cancer. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVS-7375

Taken by mouth

Locations(13)

START LA

Los Angeles, California, United States

Cedars-Sinai Medical Center

Los Angeles, California, United States

Valkyrie Clinical Trials

Los Angeles, California, United States

Emory Winship Cancer Institute

Atlanta, Georgia, United States

START New Jersey

East Brunswick, New Jersey, United States

NYU

New York, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

START Fort Worth

Fort Worth, Texas, United States

MD Anderson Cancer Center

Houston, Texas, United States

University of Virginia

Charlottesville, Virginia, United States

Chris O'Brien Lifehouse

Camperdown, New South Wales, Australia

Macquarie University Hospital

Sydney, New South Wales, Australia

ICON Cancer Centre South Brisbane

Brisbane, Queensland, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07659782

Related Trials

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

NCT075785712 locations

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

NCT0702011712 locations

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

NCT07195695199 locations

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

NCT021461701 location

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137267 locations